Abstract
Background The radiotherapy techniques are evolving. Besides optimal tumor coverage, considering organs at risk (OAR) is pertinent to radiation oncologists. In esophageal cancer radiotherapy, heart is the main OAR. Studies on excess absolute risk (EAR) of cardiovascular disease (CVD) in esophageal cancer radiotherapy are limited in the main literature. Therefore, this study was conducted to estimate the EAR of CVD in patients with esophageal cancer treated with the IMRT technique.
Materials and Methods Seventeen patients with esophageal cancer were selected. The patients were planned for the IMRT technique, and the 10-year EAR of CVD was estimated using the linear model. The data of major CVD risk factors [including age, smoking, and family history of heart attack, systolic blood pressure, total and HDL cholesterol, and high sensitivity c-reactive protein (hsCRP)] were obtained and the baseline risk of CVD was categorized into low- and high-risk groups using the Reynolds risk score.
Results Family history of heart disease and smoking increased the EAR of CVD significantly compared to the cholesterol and hsCRP. The 10-year EAR of the high-risk group was more than four times of the low-risk group at all ages. In the low-risk group, EAR of CVD after radiotherapy of esophageal cancer can increase by up to 9.1%, while in the high-risk group, EAR increased by 34.89%.
Conclusions Adding the baseline CVD risk factors improved the estimation of EAR of heart disease after esophageal cancer radiotherapy with the IMRT technique.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical approval was provided by the ethical committee of the Kurdistan University of Medical Sciences, and the study was conducted per the principles of the Declaration of Helsinki and current ethical guidelines.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
